Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WVE-210201 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| WVE-210201 (Dose A) or placebo | EXPERIMENTAL | - |
| WVE-210201 (Dose B) or placebo | EXPERIMENTAL | - |
| WVE-210201 (Dose C) or placebo | EXPERIMENTAL | - |
| WVE-210201 (Dose D) or placebo | EXPERIMENTAL | - |
| WVE-210201 (Dose E) or placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| WVE-210201 | DRUG | WVE-210201 is a stereopure antisense oligonucleotide (ASO) |
| Placebo | DRUG | Sodium Chloride |
Inclusion Criteria: * Diagnosis of Duchenne muscular dystrophy (DMD) based on clinical phenotype with increased serum creatine kinase * Documented mutation in the Dystrophin gene associated with DMD that is amenable to exon 51 skipping * Ambulatory or non-ambulatory male patients aged ≥5 - ≤18 year...
WVE-210201 is an investigational small molecule being developed for the treatment of Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive muscle degeneration and weakness. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
WVE-210201 is being developed by Wave Life Sciences Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol WVE. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in patients with Duchenne Muscular Dystrophy.
WVE-210201 is in Phase 1 clinical development. A Phase 1 trial has been completed, which assessed the safety and tolerability of the drug in patients with Duchenne Muscular Dystrophy. The drug remains investigational and has not received FDA approval.
WVE-210201 has one completed clinical trial, registered as NCT03508947, titled 'Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy.' This Phase 1 study enrolled 36 male participants aged 5 years and older across multiple countries, including the United States, Belgium, Canada, France, Italy, Netherlands, and the United Kingdom.
WVE-210201 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial information, and it is distinct from other drugs in Wave Life Sciences' pipeline.